Tumor microenvironment mechanisms and bone metastatic disease progression of prostate cancer.

[1]  S. Signoretti,et al.  A Subset of Localized Prostate Cancer Displays an Immunogenic Phenotype Associated with Losses of Key Tumor Suppressor Genes , 2021, Clinical Cancer Research.

[2]  M. Spahn,et al.  Stroma Transcriptomic and Proteomic Profile of Prostate Cancer Metastasis Xenograft Models Reveals Prognostic Value of Stroma Signatures , 2020, Cancers.

[3]  L. Hofbauer,et al.  Emerging Players in Prostate Cancer-Bone Niche Communication. , 2020, Trends in cancer.

[4]  W. Lowrance,et al.  Advanced Prostate Cancer: AUA/ASTRO/SUO Guideline PART I. , 2020, The Journal of urology.

[5]  M. McDevitt,et al.  Radiopharmaceutical therapy in cancer: clinical advances and challenges , 2020, Nature Reviews Drug Discovery.

[6]  Meng Xu,et al.  Role of αVβ3 in Prostate Cancer: Metastasis Initiator and Important Therapeutic Target , 2020, OncoTargets and therapy.

[7]  S. Srinivas,et al.  Prostate Cancer Brain Metastases: A Single-Institution Experience. , 2020, World neurosurgery.

[8]  W. Olejarz,et al.  Exosomes in Prostate Cancer Diagnosis, Prognosis and Therapy , 2020, International journal of molecular sciences.

[9]  R. Montironi,et al.  Epigenetic modulations and lineage plasticity in advanced prostate cancer. , 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  Masatoshi Watanabe,et al.  Castration-induced stromal remodeling disrupts the reconstituted prostate epithelial structure , 2019, Laboratory Investigation.

[11]  Sara Sofia Deville,et al.  The Extracellular, Cellular, and Nuclear Stiffness, a Trinity in the Cancer Resistome—A Review , 2019, Front. Oncol..

[12]  B. Helfand,et al.  Heterogeneity of human prostate carcinoma‐associated fibroblasts implicates a role for subpopulations in myeloid cell recruitment , 2019, The Prostate.

[13]  E. Schaeffer,et al.  A mouse model of prostate cancer bone metastasis in a syngeneic immunocompetent host , 2019, Oncotarget.

[14]  K. Pienta,et al.  Primary prostate cancer educates bone stroma through exosomal pyruvate kinase M2 to promote bone metastasis , 2019, The Journal of experimental medicine.

[15]  Xiaocong Pang,et al.  Identification of SPP1 as an Extracellular Matrix Signature for Metastatic Castration-Resistant Prostate Cancer , 2019, Front. Oncol..

[16]  Yuzhuo Wang,et al.  Treatment-emergent neuroendocrine prostate cancer: molecularly driven clinical guidelines , 2019, International Journal of Endocrine Oncology.

[17]  M. Stockler,et al.  Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer. , 2019, The New England journal of medicine.

[18]  L. Dang,et al.  A Single-center Retrospective Analysis of the Effect of Radium-223 (Xofigo) on Pancytopenia in Patients with Metastatic Castration-resistant Prostate Cancer , 2019, Cureus.

[19]  W. Oyen,et al.  Consensus on molecular imaging and theranostics in prostate cancer. , 2018, The Lancet. Oncology.

[20]  S. Stewart,et al.  Understanding the Bone in Cancer Metastasis , 2018, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[21]  J. Buscombe,et al.  Why should we be concerned about a “g”? , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[22]  Jan Sundquist,et al.  Clinical landscape of cancer metastases , 2018, Cancer medicine.

[23]  Jack Cuzick,et al.  Tumor copy number alteration burden is a pan-cancer prognostic factor associated with recurrence and death , 2018, eLife.

[24]  P. Nelson,et al.  Cellular Constituents of the Prostate Stroma: Key Contributors to Prostate Cancer Progression and Therapy Resistance. , 2018, Cold Spring Harbor perspectives in medicine.

[25]  H. G. van der Poel,et al.  Loss of androgen receptor signaling in prostate cancer‐associated fibroblasts (CAFs) promotes CCL2‐ and CXCL8‐mediated cancer cell migration , 2018, Molecular oncology.

[26]  A. Wetterwald,et al.  Osteolytic cancer cells induce vascular/axon guidance processes in the bone/bone marrow stroma , 2018, Oncotarget.

[27]  V. Vlaeminck-Guillem.  Extracellular Vesicles in Prostate Cancer Carcinogenesis, Diagnosis, and Management , 2018, Front. Oncol..

[28]  W. Horninger,et al.  Comparison of [68Ga]Ga-PSMA-11 PET/CT with [18F]NaF PET/CT in the evaluation of bone metastases in metastatic prostate cancer patients prior to radionuclide therapy , 2018, European Journal of Nuclear Medicine and Molecular Imaging.

[29]  Douglas K Owens,et al.  Screening for Prostate Cancer: US Preventive Services Task Force Recommendation Statement , 2018, JAMA.

[30]  L. Nakhleh,et al.  Matrilysin/MMP-7 Cleavage of Perlecan/HSPG2 Complexed with Semaphorin 3A Supports FAK-Mediated Stromal Invasion by Prostate Cancer Cells , 2018, Scientific Reports.

[31]  Masatoshi Watanabe,et al.  Role of Stromal Paracrine Signals in Proliferative Diseases of the Aging Human Prostate , 2018, Journal of clinical medicine.

[32]  J. Clohessy,et al.  Diverse genetic-driven immune landscapes dictate tumor progression through distinct mechanisms , 2018, Nature Medicine.

[33]  A. Kishan,et al.  68Ga-PSMA-11 PET/CT Mapping of Prostate Cancer Biochemical Recurrence After Radical Prostatectomy in 270 Patients with a PSA Level of Less Than 1.0 ng/mL: Impact on Salvage Radiotherapy Planning , 2017, The Journal of Nuclear Medicine.

[34]  K. Pienta,et al.  Tenascin-C and Integrin α9 Mediate Interactions of Prostate Cancer with the Bone Microenvironment. , 2017, Cancer research.

[35]  W. Wadsak,et al.  68Ga-PSMA 11 ligand PET imaging in patients with biochemical recurrence after radical prostatectomy – diagnostic performance and impact on therapeutic decision-making , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[36]  G. Parmigiani,et al.  Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer , 2017, Nature Communications.

[37]  Thomas R. Cox,et al.  Pre-metastatic niches: organ-specific homes for metastases , 2017, Nature Reviews Cancer.

[38]  T. Holland-Letz,et al.  Repeated PSMA-targeting radioligand therapy of metastatic prostate cancer with 131I-MIP-1095 , 2017, European Journal of Nuclear Medicine and Molecular Imaging.

[39]  F. Macedo,et al.  Bone Metastases: An Overview , 2017, Oncology Reviews.

[40]  H. Scher,et al.  Enzalutamide in castration‐resistant prostate cancer patients with visceral disease in the liver and/or lung: Outcomes from the randomized controlled phase 3 AFFIRM trial , 2017, Cancer.

[41]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[42]  W. Brenner,et al.  German Multicenter Study Investigating 177Lu-PSMA-617 Radioligand Therapy in Advanced Prostate Cancer Patients , 2017, The Journal of Nuclear Medicine.

[43]  S. Shiao,et al.  Regulation of prostate cancer progression by the tumor microenvironment. , 2016, Cancer letters.

[44]  C. Hsieh,et al.  Exosomes from the tumor microenvironment as reciprocal regulators that enhance prostate cancer progression , 2016, International journal of urology : official journal of the Japanese Urological Association.

[45]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[46]  F. Saad,et al.  Metastatic Prostate Cancer and the Bone: Significance and Therapeutic Options. , 2015, European urology.

[47]  Gary K. Schwartz,et al.  Tumour exosome integrins determine organotropic metastasis , 2015, Nature.

[48]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[49]  C. Pinnock,et al.  Stromal androgen receptor regulates the composition of the microenvironment to influence prostate cancer outcome , 2015, Oncotarget.

[50]  Toshimichi Yoshida,et al.  Tenascin-C and integrins in cancer , 2015, Cell adhesion & migration.

[51]  Jeroen A. A. Demmers,et al.  Proteomic signatures of extracellular vesicles secreted by nonmineralizing and mineralizing human osteoblasts and stimulation of tumor cell growth , 2015, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[52]  S. Hayward,et al.  Stromal androgen receptor in prostate development and cancer. , 2014, The American journal of pathology.

[53]  I. Holen,et al.  Castration-induced bone loss triggers growth of disseminated prostate cancer cells in bone. , 2014, Endocrine-related cancer.

[54]  David S W Djang,et al.  Newer PET application with an old tracer: role of 18F-NaF skeletal PET/CT in oncologic practice. , 2014, Radiographics : a review publication of the Radiological Society of North America, Inc.

[55]  V. Simeon,et al.  Palliative treatment of bone metastases with samarium-153 EDTMP at onset of pain , 2014, Journal of Bone and Mineral Metabolism.

[56]  P. Paoli,et al.  Tumor microenvironment and metabolism in prostate cancer. , 2014, Seminars in oncology.

[57]  W. Isaacs,et al.  Tracking the clonal origin of lethal prostate cancer. , 2013, The Journal of clinical investigation.

[58]  R. Ferracini,et al.  Solid Tumours Show Osteotropism: Mechanisms of Bone Metastases , 2013, Clinical Reviews in Bone and Mineral Metabolism.

[59]  Gerald C. Chu,et al.  Animal models of human prostate cancer: the consensus report of the New York meeting of the Mouse Models of Human Cancers Consortium Prostate Pathology Committee. , 2013, Cancer research.

[60]  A. Sivachenko,et al.  Punctuated Evolution of Prostate Cancer Genomes , 2013, Cell.

[61]  R. Cardiff,et al.  B-Raf activation cooperates with PTEN loss to drive c-Myc expression in advanced prostate cancer. , 2012, Cancer research.

[62]  Aditi Gupta,et al.  Integrin αvβ3 and CD44 pathways in metastatic prostate cancer cells support osteoclastogenesis via a Runx2/Smad 5/receptor activator of NF-κB ligand signaling axis , 2012, Molecular Cancer.

[63]  H. Hieronymus,et al.  Traversing the genomic landscape of prostate cancer from diagnosis to death , 2012, Nature Genetics.

[64]  A. Sivachenko,et al.  Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer , 2012, Nature Genetics.

[65]  J. Staffurth,et al.  A randomized, dose-response, multicenter phase II study of radium-223 chloride for the palliation of painful bone metastases in patients with castration-resistant prostate cancer. , 2012, European journal of cancer.

[66]  S. Abdulkadir,et al.  A mouse model of heterogeneous, c-MYC-initiated prostate cancer with loss of Pten and p53 , 2011, Oncogene.

[67]  M. Carducci,et al.  Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study , 2011, The Lancet.

[68]  F. Marshall,et al.  Human prostate fibroblasts induce growth and confer castration resistance and metastatic potential in LNCaP Cells. , 2010, European urology.

[69]  L. Chung,et al.  Tumor-stroma co-evolution in prostate cancer progression and metastasis. , 2010, Seminars in cell & developmental biology.

[70]  D. Ornstein,et al.  The increased expression of periostin during early stages of prostate cancer and advanced stages of cancer stroma , 2009, The Prostate.

[71]  W. Ellis,et al.  Disseminated Tumor Cells in Prostate Cancer Patients after Radical Prostatectomy and without Evidence of Disease Predicts Biochemical Recurrence , 2009, Clinical Cancer Research.

[72]  R. Matusik,et al.  Stromal transforming growth factor-beta signaling mediates prostatic response to androgen ablation by paracrine Wnt activity. , 2008, Cancer research.

[73]  T. Wheeler,et al.  Stromogenic prostatic carcinoma pattern (carcinomas with reactive stromal grade 3) in needle biopsies predicts biochemical recurrence-free survival in patients after radical prostatectomy. , 2007, Human pathology.

[74]  Matthew J. Craig,et al.  Targeting CCL2 with systemic delivery of neutralizing antibodies induces prostate cancer tumor regression in vivo. , 2007, Cancer research.

[75]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[76]  K. Pienta,et al.  CCL2 is a potent regulator of prostate cancer cell migration and proliferation. , 2006, Neoplasia.

[77]  O. MacDougald,et al.  Role of wnts in prostate cancer bone metastases , 2006, Journal of cellular biochemistry.

[78]  Yi Lu,et al.  Bone morphogenetic protein-6 promotes osteoblastic prostate cancer bone metastases through a dual mechanism. , 2005, Cancer research.

[79]  D. Horsfall,et al.  Androgen receptor levels in prostate cancer epithelial and peritumoral stromal cells identify non‐organ confined disease , 2005, The Prostate.

[80]  C. Hughes,et al.  Of Mice and Not Men: Differences between Mouse and Human Immunology , 2004, The Journal of Immunology.

[81]  S. Abdulkadir,et al.  Notch Signaling and ERK Activation Are Important for the Osteomimetic Properties of Prostate Cancer Bone Metastatic Cell Lines* , 2004, Journal of Biological Chemistry.

[82]  T. Graeber,et al.  Myc-driven murine prostate cancer shares molecular features with human prostate tumors. , 2003, Cancer cell.

[83]  J. Moul,et al.  Limited value of bone scintigraphy and computed tomography in assessing biochemical failure after radical prostatectomy. , 2003, Urology.

[84]  M. Blagosklonny.  Oncogenic resistance to growth-limiting conditions , 2002, Nature Reviews Cancer.

[85]  T. Hara,et al.  PET imaging of prostate cancer using carbon-11-choline. , 1998, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[86]  C. Perez-stable,et al.  Prostate cancer progression, metastasis, and gene expression in transgenic mice. , 1997, Cancer research.

[87]  J. Rosen,et al.  Metastatic prostate cancer in a transgenic mouse. , 1996, Cancer research.

[88]  W. Fair,et al.  Expression of the prostate-specific membrane antigen. , 1994, Cancer research.

[89]  D. Paulson,et al.  Isolation of a human prostate carcinoma cell line (DU 145) , 1978, International journal of cancer.

[90]  A. Fatatis,et al.  The Bone Microenvironment in Prostate Cancer Metastasis. , 2019, Advances in experimental medicine and biology.

[91]  S. Manolagas,et al.  Activation of the Janus kinase/STAT (signal transducer and activator of transcription) signal transduction pathway by interleukin-6-type cytokines promotes osteoblast differentiation. , 1997, Endocrinology.